Clinical Trials

NCT Number: NCT05691465 Phase: Phase 2 Trial Summary: This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation (formed from cells that release hormones into the bloo – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): National Cancer Institute (NCI) Acronym:

NCT Number: NCT05785741 Phase: Phase 1|Phase 2 Trial Summary: This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): DualityBio Inc. Acronym:

NCT Number: NCT05787587 Phase: Phase 1 Trial Summary: The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): IDEAYA Biosciences Acronym:

NCT Number: NCT05804318 Phase: Not Applicable Trial Summary: This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Varian, a Siemens Healthineers Company Acronym: ARTIA-Prostate

NCT Number: NCT04705038 Phase: Not Applicable Trial Summary: The purpose of this study is to learn how an educational intervention about orchiectomy as an alternative to medical castration for those who are already on medical castration will impact the number o – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Chicago Acronym:

NCT Number: NCT04969835 Phase: Phase 1 Trial Summary: This open-label, First-into-Human (FIH) study will evaluate the safety, tolerability, pharmacokinetics (PK) and early efficacy of AVA6000, a FAP-activated pro-drug of doxorubicin, in patients with loc – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Avacta Life Sciences Ltd Acronym:

NCT Number: NCT04981223 Phase: Not Applicable Trial Summary: The goal of this study is to use a clinical micro-ultrasound to systematically image the prostate before biopsy or surgery. The images from the ultrasound system will be saved and compared to other im – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Stanford University Acronym:

NCT Number: NCT05800665 Phase: PHASE1 Trial Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also ide – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Genentech, Inc. Acronym:

NCT Number: NCT05823402 Phase: NA Trial Summary: The SPECTacular study will enroll patients who are already undergoing a FDA approved PSMA-targeted Radioligand treatment cycle. During each treatment cycle, patients will receive 5 additional SPECT/CT – clinicaltrials.gov for more Clinicaltrials.gov Trial Sponsor(s): BAMF Health Acronym: SPECTacular

NCT Number: NCT05826470 Phase: NA Trial Summary: Trans-perineal focal laser ablation represents a promising alternative focal therapy option for patients with low-risk or favorable intermediate risk prostate cancer. FLA has been extensively utilized – clinicaltrials.gov for more Clinicaltrials.gov Trial Sponsor(s): Genesis Research LLC Acronym: